Endogenous α1-antitrypsin levels in the perilymphatic fluid correlates with severity of hearing loss.
autoinflammation
congenital deafness
hearing loss
perilymph
α1-antitrypsin
Journal
Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
ISSN: 1749-4486
Titre abrégé: Clin Otolaryngol
Pays: England
ID NLM: 101247023
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
06
10
2019
revised:
09
03
2020
accepted:
14
03
2020
pubmed:
5
4
2020
medline:
24
8
2021
entrez:
5
4
2020
Statut:
ppublish
Résumé
To determine the levels of endogenous α1-antitrypsin in the perilymph of patients undergoing cochlear implant (CI), and its reverse association with the severity of hearing loss. Retrospective study. Tertiary care university hospital. The study includes 38 patients undergoing CI surgery, 11 patients diagnosed with congenital deafness and 27 non-congenital deafness, eight patients diagnosed with moderate hearing loss (N = 8; PTA = 70 dB), severe hearing loss (N = 11; PTA 70-90 dB) and profound hearing loss (N = 19; PTA > 90 dB). 1 to 12 μL perilymphatic fluids were collected by micropipette. α1-antitrypsin levels were determined, and current and historic audiological parameters were obtained. The congenital and non-congenital group exhibited AAT concentrations of 2.5 ± 1.9 × 10 Insufficiency in α1-antitrypsin levels in the perilymph fluid of the inner ear appears to display a relationship with the severity of hearing loss. The prospect of introducing clinical-grade plasma-purified α1-antitrypsin directly onto the site of cochlear injury deserves thorough investigation.
Substances chimiques
C105Y peptide
0
Peptide Fragments
0
alpha 1-Antitrypsin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
495-499Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Schmitt HA, Pich A, Schroder A, et al. Proteome analysis of human perilymph using an intraoperative sampling method. J Proteome Res. 2017;16(5):1911-1923.
Gettins PG. Serpin structure, mechanism, and function. Chem Rev. 2002;102(12):4751-4804.
Sha SH, Qiu JH, Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med. 2006;354(17):1856-1857.
Suh DY, Hunt TK, Spencer EM. Insulin-like growth factor-I reverses the impairment of wound healing induced by corticosteroids in rats. Endocrinology. 1992;131(5):2399-2403.
Lewis EC. Alpha1-antitrypsin therapy for non-deficient individuals: integrating and mitigating cross-pathology inflammatory and immune responses to the injured cell. Int Med Rev. 2017;3(5):1.
Lebenthal Y, Brener A, Hershkovitz E, et al. A phase II, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of Alpha-1 antitrypsin (AAT) (Glassia((R))) in the treatment of recent-onset type 1 diabetes. Int J Mol Sci. 2019;20(23).
Plaut AG, Qiu J, St Geme JW 3rd. Human lactoferrin proteolytic activity: analysis of the cleaved region in the IgA protease of Haemophilus influenzae. Vaccine. 2000;19(Suppl 1):S148-S152.
Hamaguchi Y, Sakakura Y. Neutrophil elastase and its complex with alpha 1-antitrypsin in the pathogenesis of chronic suppurative otitis media. Ann Otol Rhinol Laryngol Suppl. 1992;157:26-31.
Miyajima S, Akaike T, Matsumoto K, et al. Matrix metalloproteinases induction by pseudomonal virulence factors and inflammatory cytokines in vitro. Microb Pathog. 2001;31(6):271-281.
Doring G. Serine proteinase inhibitor therapy in alpha(1)-antitrypsin inhibitor deficiency and cystic fibrosis. Pediatr Pulmonol. 1999;28(5):363-375.
Ma S, Lin YY, Cantor JO, et al. The effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trials. Chronic Obstr Pulm Dis. 2016;4(1):34-44.
Antonelli PJ, Schultz GS, Kim KM, et al. Alpha 1-antitrypsin and ilomastat inhibit inflammatory proteases present in human middle ear effusions. Laryngoscope. 2003;113(8):1347-1351.